

Ref: BF/PSX/I-01  
Date: April 11, 2025

**The General Manager,**  
Pakistan Stock Exchange Limited,  
Stock Exchange Building,  
Stock Exchange Road,  
Karachi.

**Subject: Submission of Quarterly Progress Report as of December 31, 2024**


Dear Sir,


We are pleased to submit the quarterly progress report as of December 31, 2024, along with the Agreed-Upon Procedures Report issued by our auditors, M/s KPMG Taseer Hadi & Co., on the implementation status.

This progress report is being submitted in compliance with the requirements of Clause 16 of "Post-Issue Reporting and Disclosures" of the "Public Offering Regulations, 2017" and in pursuance of the requirement specified in clause 4.5.1 of the "Prospectus For Initial Public Offering" of BF Biosciences Limited.

Thank you.

For and on behalf of BF Biosciences Limited

  
**Abdur Rehman**  
Company Secretary



☐ **Head Office/Biotech Factory:**

5 - KM, Sundar Raiwind Road  
Raiwind (55150), Pakistan  
Tel: (+92 42) 3602 6700  
Fax: (+92 42) 3602 6701-02

☐ **Registered Office:**

197 - A, The Mall, Rawalpindi  
(46000), Pakistan  
Tel: (+92 51) 4252 155-57  
Fax: (+92 51) 4252 153

☐ **Lahore Sales Office:**

43 - Al Noor Building, Bank  
Square, The Mall, Lahore  
(54000), Pakistan  
Tel: (+92 42) 3735 8194  
Fax: (+92 42) 3731 3680

☐ **Karachi Sales Office:**

House No. 9, Maqbool Cooperative  
Housing Society, Shahrah-e-Faisal  
Karachi (75350), Pakistan  
Tel: (+92 21) 3438 6852  
Fax: (+92 21) 3438 6754



KPMG Taseer Hadi & Co.  
Chartered Accountants  
351 Shadman-1, Jail Road,  
Lahore 54000 Pakistan  
+92 (42) 111-KPMGTH (576484), Fax +92 (42) 3742 9907

The Chief Executive Officer  
BF Biosciences Limited  
197-A, The Mall  
Rawalpindi

Our ref LA-IA-115-25

Contact Ahsin Tariq

09 April 2025

Honorable Members of the Board

**BF Biosciences Limited ("the Company")**  
**Agreed-Upon Procedures Report on Progress Report for the period till 31 December 2024**

**1. Purpose of this Agreed-Upon Procedures Report and Restriction on Use and Distribution**

Our report is solely for the purpose of assisting BF Biosciences Limited ("the Company") in meeting the requirements of clause 16 'Post issue Reporting and Disclosures' of the Public Offering Regulation, 2017 and in pursuance of the requirement in clause 4.5.1 of the prospectus of the Company dated 19 September 2024. Accordingly, our report will be addressed to you and our report is not to be used for any other purpose or should not be distributed to any other party.

**2. Responsibility of the Engaged Party**

The Company's management has acknowledged that the agreed-upon procedures are appropriate for the purpose of the engagement.

The Company's management is responsible for the subject matter on which agreed-upon procedures are performed.

**3. Practitioner's Responsibilities**

We have conducted the agreed-upon procedures engagement in accordance with the International Standard on Related Services (ISRS) 4400 (revised) "Agreed-Upon Procedures Engagement". An agreed-upon procedures engagement involves our performing the procedures that have been agreed with management of the Company, and reporting the findings, which are the factual results of the agreed-upon procedures performed. We make no representation regarding the appropriateness of the agreed-upon procedures.

This agreed-upon procedures engagement is not an assurance engagement. Accordingly, we do not express an opinion or an assurance conclusion.

Had we performed additional procedures; other matters might have come to our attention that would have been reported.





KPMG Taseer Hadi & Co.

#### 4. Professional Ethics and Quality Management

We have complied with the ethical requirements of the International Ethics Standards Board for the Accountants' Code of Ethics for Professional Accountants as adopted by the Institute of Chartered Accountants of Pakistan. For the purpose of this engagement, there are no independence requirements with which we are required to comply.

Our firm applies International Standard on Quality Management (ISQM) 1 "Quality Management for Firms that Perform Audits or Reviews of Financial Statements, or Other Assurance or Related Services Engagements" which requires the firm to design, implement and operate a system of quality management including policies or procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

#### 5. Procedures and findings

We have performed the procedures described below, which were agreed upon with the management of the Company in terms of engagement letter dated 26 February 2025 on the Progress Report containing implementation status of the project, as disclosed in the prospectus, till 31 December 2024 ('the Progress Report').

Sr. No.	Procedures	Findings
1	Obtain the following from the management: <ul style="list-style-type: none"><li>- The Progress Report for the period till 31 December 2024.</li><li>- Books of account from 21 October 2024 to 31 December 2024 of the relevant expansion project as identified under the heading 'Implementation status' of the Projects; and</li><li>- Prospectus for the issue of shares dated 19 September 2024.</li></ul>	We have obtained: <ul style="list-style-type: none"><li>- The Progress Report for the period ended 31 December 2024.</li><li>- Books of account of the Company for period ended 31 December 2024 of the relevant expansion project as identified under the heading of 'Implementation status' of the Progress Report; and</li><li>- Prospectus for issue of shares dated 19 September 2024 ('the Prospectus').</li></ul>
	<ul style="list-style-type: none"><li>- Matching the amount shown as funds required under the heading of 'Implementation status' on the Progress Report with the Prospectus.</li></ul>	<ul style="list-style-type: none"><li>- We have matched the amount shown as funds required under the heading of 'Implementation status' on the Progress Report with the Prospectus and no differences were found.</li></ul>
	<ul style="list-style-type: none"><li>- Matching actual expenditure incurred till 31 December 2024 for the relevant expansion project as identified under the heading of 'Implementation status' of the Progress Report with the Progress Report for the period ended 31 December 2024, and books of accounts of the relevant expansion project for the period ended 31 December 2024.</li></ul>	<ul style="list-style-type: none"><li>- We have matched actual expenditure incurred till 31 December 2024 for the relevant expansion project as identified under the heading of 'Implementation status' of the Progress Report with the Progress Report for the period ended 31 December 2024, and books of accounts of the relevant expansion project for the period ended 31 December 2024.</li></ul>

KPMG




KPMG Taseer Hadi & Co.

Sr. No.	Procedures	Findings
	- Recalculating the allocation percentage as shown under the heading of 'Implementation status' by dividing 'Funds required' against each expansion project with the 'Total Funds' required for completion of project.	- We have recalculated the allocation percentage as shown under the heading of 'Implementation status' by dividing 'Funds required' against each expansion project with the 'Total Funds' required for the completion of project and no differences were found.

Lahore

Date: 09 April 2025

  
KPMG Taseer Hadi & Co.  
Chartered Accountants



**BF Biosciences Limited**

**Quarterly / Half Yearly Progress Report  
For The Period Ended 31 December 2024**

## Table of Contents:

### Contents

Preamble .....	3
Summary of IPO Funds Utilization .....	4
Implementation Status .....	4
• Purchase of Plant and Machinery .....	4
1. Inspection Machine.....	5
2. Pre-filled Syringes Machine Cartridge System .....	5
3. Change Parts – Filling Machine .....	5
4. Quality Control Equipment .....	5
5. Formulation Vessel & UPS.....	5
6. Walkthrough Gates .....	5
7. Stability Chambers .....	5
8. Filling Line System Upgradation for Line I.....	5
9. Cartridge Machine for Pre-filled Syringes Machine .....	6
10. Installation / Contingency .....	6
• Obtaining Export related Certifications and New Product Developments .....	6
• Managing Working Capital Requirements .....	6

## Preamble

We are pleased to share the quarterly / half-yearly progress report for the period ended 31 December 2024. This progress report is being submitted in compliance with the requirement of Clause 16 (ii) of “Post-Issue Reporting and Disclosures” of the “Public Offering Regulations, 2017” and in pursuance of the requirement specified in clause 4.5.1 of the “Prospectus For Initial Public Offering” of BF Biosciences Limited (“the Company”).

The Company’s Initial Public Offering was concluded in October 2024, whereby gross proceeds amounting to Rs. 1,925,000,000 (Rupees One Billion Nine Hundred Twenty-Five Million Only) were raised.

The details of planned purpose along with the breakup of net funds raised is as follows:

Sr. No.	Purpose	Amounts (Rs.)	Allocation Percentage (%)
1	Purchase of Plant and Machinery	697,879,105	36.3%
2	Obtaining Export related Certifications and New Product Developments	140,800,000	7.3%
3	Managing Working Capital Requirements	1,086,320,895	56.4%
	<b>Grand Total</b>	<b>1,925,000,000</b>	<b>100.0%</b>
	<b>Less: Transactions Costs Incurred</b>	<b>(69,801,865)</b>	
	<b>Net IPO Proceeds Raised</b>	<b>1,855,198,135</b>	



## Summary of IPO Funds Utilization

The status of IPO funds utilization as of December 31, 2024 is as follows:

Sr. No.	Purpose	Allocated Costs (Rs.)	Funds Utilized (Rs.)	Funds Available (Rs.)
1	Purchase of Plant and Machinery	697,879,105	(66,634,965)	631,244,140
2	Obtaining Export related Certifications and New Product Developments	140,800,000	(8,913,361)	131,886,639
3	Managing Working Capital Requirements	1,086,320,895	(631,794,978)	454,525,917
	<b>Grand Total</b>	<b>1,925,000,000</b>	<b>(707,343,304)</b>	<b>1,217,656,696</b>

## Implementation Status

The implementation status of each planned line item is as follows:

- Purchase of Plant and Machinery

The summary of asset-wise detail relating to plant and machinery is as follows:

Sr. No.	Purpose	Allocated Costs (Rs.)	Allocation Percentage (%)	Funds Utilized (Rs.)	Funds Available (Rs.)	Timelines (Start – Finish)
1	Inspection Machine	115,990,875	16.62%	-	115,990,875	Q3 FY 25 - Q1 FY 26
2	PFS Machine Cartridge System	126,535,500	18.13%	-	126,535,500	Q3 FY 25 - Q1 FY 26
3	Change Parts – Filling Machine	35,100,000	5.03%	(7,202,400)	27,897,600	Q1 FY 25 - Q4 FY 25
4	Quality Control Equipment	43,082,325	6.17%	(30,565,579)	12,516,746	Q2 FY 25 - Q4 FY 25
5	Formulation Vessel & UPS	126,535,500	18.13%	(4,436,800)	122,098,700	Q3 FY 25 - Q1 FY 26
6	Walkthrough Gates	8,775,000	1.26%	-	8,775,000	Q2 FY 25 - Q4 FY 25
7	Stability Chambers	7,020,000	1.01%	(4,380,750)	2,639,250	Q4 FY 24 - Q2 FY 25
8	Filling Line System Upgradation for Line I	46,396,350	6.65%	-	46,396,350	Q2 FY 25 - Q4 FY 25
9	Cart. Machine for PFS	137,500,000	19.70%	-	137,500,000	Q3 FY 25 - Q1 FY 26
10	Installation / Contingency	50,943,555	7.30%	(20,049,436)	30,894,119	Q2 FY 25 - Q1 FY 26
	<b>Grand Total</b>	<b>697,879,105</b>	<b>100%</b>	<b>(66,634,965)</b>	<b>631,244,140</b>	



The progress of each asset is explained below:

1. Inspection Machine

The user requirement specifications (URS) for inspection machine have been finalized and currently management is seeking quotations and finalizing vendor. The management is confident to achieve completion within the communicated timeline (i.e. Q1 FY 26).

2. Pre-filled Syringes Machine Cartridge System

The technical design of the cartridge system is in finalization with the manufacturer, after which procurement process will be started. The management is confident to achieve completion within the communicated timeline (i.e. Q1 FY 26).

3. Change Parts – Filling Machine

Order along with advance payment against change parts for filling machine have been successfully made and the management is confident to achieve completion within the communicated timeline (i.e. Q4 FY 25).

4. Quality Control Equipment

Majority of the quality control equipment have been purchased, whereas few other equipment is pending, of which procurement is in process. The management is confident to achieve the communicated timeline (i.e. Q4 FY 25).

5. Formulation Vessel & UPS

The partial order of formulation vessels has been placed, once these are delivered by end of March 2025 and based on the results, the Company will procure additional vessels. Furthermore, order relating to UPS has been placed and delivery is expected by end of March 2025. The management is confident to achieve full completion within the communicated timeline (i.e. Q1 FY 26).

6. Walkthrough Gates

The quotations relating to walkthrough gates are being taken currently, and the management is confident to achieve completion within the communicated timeline (i.e. Q4 FY 25).

7. Stability Chambers

Majority of the planned stability chambers have been purchased, whereas others are in procurement phase. The management is confident to achieve the communicated timeline (i.e. Q2 FY 25).

8. Filling Line System Upgradation for Line I

The order for filling line system upgradation has been successfully placed, and the visit of foreign engineers is expected during Q3 FY 2025. The management is confident to achieve completion within the communicated timeline (i.e. Q4 FY 25).

#### 9. Cartridge Machine for Pre-filled Syringes Machine

Reference is made to the response mentioned in point 2 above 'Pre-filled Syringes Machine Cartridge System', there are certain technological developments post IPO regarding the product mix for cartridge lines. Accordingly, the decision will be made by the management after assessment under the above said point 2 above.

#### 10. Installation / Contingency

Several other ancillary equipment / spares are being purchased on as and when required basis, and the management is confident to achieve completion within the communicated timeline (i.e. Q1 FY 26).

- **Obtaining Export related Certifications and New Product Developments**

In order to acquire export certifications, consultants have been duly appointed by the Company who have completed the gap analysis. The Company is currently working on the gaps identified by the consultant along with dossier preparations for Stringent Regulatory Authority (SRA) filings.


As far as new product developments are concerned, the Company is working on Tirzeptide (GLP-1, GIP) along with other molecules. A number of new products have also been launched during the current financial year as well.

The management is confident to achieve completion within the communicated timeline (i.e. Q4 FY 26).


- **Managing Working Capital Requirements**

The Company is continuously procuring raw and packing materials for managing its market needs. As of reporting date, 58% of the planned IPO funds have been duly utilized for managing working capital needs. Going forward, the management is confident to achieve completion within the communicated timeline (i.e. Q4 FY 25).

For and on behalf of **BF Biosciences Limited**



**Abdur Rehman**  
CFO & Company Secretary



**Muhammad Farhan Rafiq**  
Chief Operating Officer